Replies to post #267745 on Avid Bioservices Inc (CDMO)

[biopharm]

BMY did the opposite and has given PD-L1 up, probably due to the Medarex story. That could become a regrettable decision in the future.

PS Targeting and IO Combos

I believe you will be correct in regards to Microsoft because Adaptive Biotechnologies to Roche with help from AI and biomarkers required PS Targeting data to build the AI data

I look forward to hearing about Oncologie nondisclosed partners

Royalties and Milestones where the CDMO is all based upon PS Targeting and more hidden behind the John Springs Stafford show